Myeloid Differentiation Factor 88 (MYD88) Gene Mutation in Diffuse Large B-Cell Lymphomas: Should it be Included in Routine?

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adults, accounting for 35% –40% of all cases. NF-κB constitutive activation is the most important alteration found in ABC DLBCL. Some genes are inactivated by somatic mutations and deletions such as TNFAIP3 (30% of cases), others, such as CARD11 (10% of cases), CD79B and CD79A (∼20% of cases), and MYD88 L265P (6-30% of c ases) are activated mostly by somatic mutations. MYD88 mutations are usually described in DLCBL ABC subtype and extranodal disease.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Laura Fogliatto, Marines Barra, Yuri Strey, Paula Oliveira, Israel Bendit, Camila Bender, Kamila Grokoski, Tito Costa, Andrea Kramer, Claudia Bica Source Type: research